Career history of Gary Abromovitz
Former positions of Gary Abromovitz
| Companies | Position | Start | End |
|---|---|---|---|
| HELEN OF TROY LIMITED | Director/Board Member | 1989-12-31 | 2022-08-23 |
| Independent Dir/Board Member | 1989-12-31 | 2022-08-23 | |
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Director/Board Member | 2005-01-31 | 2012-08-09 |
| Independent Dir/Board Member | 2005-01-31 | 2012-08-09 |
Statistics
International
| Bermuda | 2 |
| United States | 2 |
Operational
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
Sectoral
| Consumer Durables | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| HELEN OF TROY LIMITED | Consumer Durables |
| Private companies | 1 |
|---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Stock Market
- Insiders
- Gary Abromovitz
- Experience
